CLL / SLL Treatment and Research
Advancements are happening everyday
Treatment and research are intimately linked. The best treatments today may be upstaged by new therapies discovered in research in the future. Take your time to learn about treatment options currently available and new ones that are on the way.
Advancements are happening everyday
Treatment and research are intimately linked. The best treatments today may be upstaged by new therapies discovered in research in the future. Take your time and learn about what treatment options are now available and the new ones are on the way.
Treatment and Research: 4 Things to Know
CLL patients are living longer than ever.
The life expectancy of patients diagnosed with CLL / SLL has improved every decade, largely because of improved care made possible by new treatments and research.
CLL treatments are better than ever.
In almost every setting and in almost every subgroup studied, the newer targeted therapies approved since 2015 have proven superior to older protocols using chemotherapy.
Better single agents and drug combinations show promise.
New improved medications and drug combinations are constantly improving outcomes.
Research drives success.
CLL / SLL is not a solved problem and never will be without new treatments and more research.
CLL patients are living longer than ever.
The life expectancy of patients diagnosed with CLL / SLL has improved every decade, largely because of improved care made possible by new treatments and research.
CLL treatments are better than ever.
In almost every setting and in almost every subgroup studied, the newer targeted therapies approved since 2015 have proven superior to older protocols using chemotherapy.
Better single agents and drug combinations show promise.
New improved medications and drug combinations are constantly improving outcomes.
Research drives success.
CLL / SLL is not a solved problem and never will be without new treatments and more research.
FEATURE
AMPLIFY Trial: Acalabrutinib Plus Venetoclax for CLL
The Bottom Line:
Acalabrutinib combined with venetoclax, with or without obinutuzumab, could lead to the FDA approval of the first all-oral frontline CLL therapy. The AMPLIFY clinical trial demonstrated that this combination therapy is very effective and well tolerated. The addition of the IV monoclonal antibody obinutuzumab (Gazyva) improves efficacy but at the cost of increased infection risk for those with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL).
Who Performed the Research and Where Was it Presented:
Dr. Jennifer Brown from Dana Farber, Boston, MA, led an international group of investigators in this large registration (for therapy approval) trial. She gave an oral presentation of the research at ASH, the American Society of Hematology Annual Meeting and Exposition, held in San Diego, CA, in December 2024.
ADDITIONAL READING
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
